ArticleDiscover oncology2025
LncRNA NEAT1 modulates myeloma cell autophagy and apoptosis by competitively binding miR-195-5p to regulate CEBPA.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Defining the RNA Modification Landscape of Multiple Myeloma Reveals METTL3-Dependent mbioRxiv : the preprint server for biology · 2026Article
- Identification of ceRNA Regulatory Networks Driven by the lncRNA NEAT1 in Multiple Myeloma.Journal of cellular and molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study explores the molecular mechanism by which lncRNA NEAT1 modulates the expression of the transcription factor CEBPA through competitive binding with miR-195-5p, thereby influencing multiple myeloma (MM) cell autophagy and apoptosis.
methodsNEAT1 knockdown was achieved using small interfering RNA (siRNA), while miRNA mimics/inhibitors were introduced into MM cells. Molecular expression levels were analyzed using qRT-PCR and Western blot. Targeting relationships were validated using dual-luciferase reporter assays. Additionally, functional assays assessed alterations in cellular responses. Moreover, a nude mouse subcutaneous xenograft model was used to evaluate intervention effects in vivo.
resultsNEAT1 knockdown suppressed proliferation and invasion while inducing apoptosis in MM cells, accompanied by impaired autophagic flux. Mechanistically, NEAT1 was competitively bound to miR-195-5p, thereby alleviating its transcriptional repression of CEBPA and subsequently enhancing CEBPA mRNA stability and upregulating protein expression. miR-195-5p overexpression replicated NEAT1 knockdown effects, whereas CEBPA silencing completely abrogated miR-195-5p’s antitumor activity. In vivo experiments further demonstrated that NEAT1 silencing reduced tumor volume, and the administration of miR-195-5p agonists decreased tumor mass. CEBPA protein expression in tumor tissue dropped by 41.6%, with concomitant reductions in the autophagic markers LC3-II and Beclin-1.
conclusionNEAT1 functions as a ceRNA to derepress miR-195-5p, alleviating its suppression of CEBPA. This, in turn, synergistically blocks autophagy flux and activates apoptosis, significantly inhibiting MM progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.